#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
CS
proLékaře.cz / Journals / Journal of Czech Physicians / 2018 - 8

Current status of cytoreductive surgery (CRS) and intraperitoneal hyperthermic chemotherapy (HIPEC) in the multimodal treatment of peritoneal surface malignancies

Czech version

Authors: Dušan Klos 1;  Juraj Riško 1;  Martin Stašek 1;  Martin Loveček 1;  Jan Hanuliak 1;  Pavel Skalický 1;  Radmila Lemstrová 2;  Beatrice Duchoňová Mohelníková 2;  Hana Študentová 2;  Čestmír Neoral 1;  Bohuslav Melichar 2
Authors‘ workplace: I. chirurgická klinika LF UP a FN Olomouc 1;  Onkologická klinika LF UP a FN Olomouc 2
Published in: Čas. Lék. čes. 2018; 157: 419-428
Category: Review Article

Overview

The tumors of the peritoneal surface, both primary and secondary, are associated with a very poor prognosis and rapid progression through conventional oncology treatment including systemic chemotherapy, targeted treatment, radiotherapy, surgery, and symptomatic treatment. Until recently, most of them were considered incurable. In the 1980s, the first cytoreductive surgery ("CRS") combined with intraperitoneal hyperthermic chemotherapy ("HIPEC") became the standard of treatment for selected tumor peritoneal tumor (pseudomyxoma peritonei and primary peritoneal malignant mesothelioma). In some cases of other peritoneal carcinomatosis associated with colorectal cancer, gastric cancer and ovarian cancer in the subgroup of well selected patients, this treatment can lead to a significant prolongation of overall survival and good standard of quality of life. This method is safe in specialized centers with an acceptable rate of morbidity and mortality comparable to foreign workplaces and is also available for patients in the Czech Republic.

Key words

surgery, oncology, cytoreduction, intraperitoneal chemotherapy, hyperthermia

Sources
  1. Spratt JS, Adcock RA, Muskovin M et al. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res 1980; 40: 256–260.
  2. Raptopoulos V. Peritoneal mesothelioma. Crit Rev Diagn Imaging 1985; 24: 293–328.
  3. Seidman JD, Zhao P, Yemelyanova A et al. Primary peritoneal high-grade serous carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma: assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening for OC. Gynecol Oncol 2011; 120: 470–473.
  4. Mačák J, Mukenšnábl P, Kawano N et al. Intraabdominální dezmoplastický malobuněčný nádor peritonea. Česko-slovenská patologie 2003; (2): 69–75.
  5. Lal DR, Su WT, Wolden SL et al. Results of multimodal treatment for desmoplastic small round cell tumors. J Pediatr Surg 2005; 40: 251–255.
  6. Bilimoria MM, Holtz DJ, Mirza NQ et al. Tumor volume as a prognostic factor for sarcomatosis. Cancer 2002; 94: 2441–2446.
  7. Carr NJ, Bibeau F, Bradley RF et al. The histopathological classification, diagnosis and differential diagnosis of mucinous appendiceal neoplasms, appendiceal adenocarcinomas and pseudomyxoma peritonei. Histopathology 2017; 71: 847–858.
  8. Lemmens VE, Klaver YL, Verwaal VJ et al. Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population based-study. Int J Cancer 2011; 128: 2717–2725.
  9. Segelman J, Granath F, Holm T et al. Incidence, prevalence and risk factors for peritoneal carcinomatosis from cancer. Br J Surg 2012; 99: 699–705.
  10. Koppe MJ, Boermann OC, Oyen WJ et al. Peritoneal carcinomatosis of colorectal origin and current treatment strategies. Ann Surg 2006; 243: 212–222.
  11. Kerscher AG, Chua TC, Gasser M et al. Impact of peritoneal carcinomatosis in the disease history of colorectal cancer management: a longitudinal experience of 2406 patients over two decades. Br J Cancer 2013; 108: 1432–1439.
  12. Hampes D, Tiek J, Wolthuis A et al. HIPEC in T4a colon cancer: a defendable treatment to improve oncologic outcome? Ann Oncol 2013; 23: 3123–3129.
  13. Thomassen I, van Gistel YR, van Ramshorst B et al. Peritoneal carcinomatosis of gastric origin: A population-based study on incidence, survival and risk factors. Int J Cancer 2014; 134: 622–628.
  14. International Agency for Research on Cancer. Dostupné na: www.iarc.fr
  15. Sherer DM, Abulafia O, Eliakim R. Pseudomyxoma peritonei: a review of current literature. Gynecol Obstet Invest 2001; 51: 73–80.
  16. Boffetta P. Epidemiology of peritoneal mesothelioma: a review. Ann Oncol 2007; 18: 985–990.
  17. Marin D, Catalano C, Kaski M et al. 64-section multi-detector row CT in the preoperative diagnosis of peritoneal carcinomatosis: correlation with histopathological findings. Abd Imaging 2010; 35: 694–700.
  18. Fujii S, Matsusue E, Kanasaki Y et al. Detection of peritoneal dissemination in gynecological malignancies: evaluation by diffusion-weighted MR imaging. Eur Radiol 2008; 18: 18–23.
  19. Kitajima K, Murakami K et al. Present and future of FDG-PET/CT in ovarian cancer. Ann Nucl Med 2011; 25: 155–164.
  20. Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. In: Sugarbaker PH (ed.). Peritoneal carcinomatosis: principles of management. Kluwer, Boston, 1996: 359–374.
  21. Baratti D, Kusamura S, Migrone E et al. Identification of a subgroup of patients at highest risk for complications after surgical cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg 2012; 256: 334–341.
  22. Sugarbaker PH. Peritonectomy procedures. Cancer Treat Res 2007; 134: 247–264.
  23. Kusamura S, Baratti D, Deraco M. Multidimensional analysis of the learning curve for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal surface malignancies. Ann Surg 2012; 255: 348–356.
  24. Sugarbaker PH, van der Speeten K. Surgical technology of hyperthermic perioperative chemotherapy. J Gastrointest Oncol 2016; 7: 29–44.
  25. Norton L, Simon R, Brereton HD et al. Predicting the course of Gompertzian growth. Nature 1976; 264: 542–545.
  26. Norton L, Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep 1986; 70: 163–169.
  27. Tanaka K, Inoue Y, Toiyama J. The role of cytoreduction for metastatic and recurrent colorectal cancer in the era of multidisciplinary treatments. J Clin Oncol 2010; 28 (15 Suppl.): e14091.
  28. Dedrick RL, Myers CE, Bungay PM et al. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 1978; 62: 1–11.
  29. Sugarbaker PH, van der Speeten K, Anthony Stuart O et al. Impact of surgical and clinical factors on the pharmacology of intraperitoneal doxorubicin in 145 patients with peritoneal carcinomatosis. Eur J Surg Oncol 2011; 37: 719–726.
  30. Sticca RP, Dach BW. Rational for hyperthermia with intraoperative intraperitoneal chemotherapy agents. Surg Oncol N Am 2003; 12: 689–701.
  31. Kampinga HH. Cell biological effects of hyperthermia alone or combined with radiation or drugs: a short introduction to newcomer in the field. Int J Hyperthermia 2006; 22: 191–196.
  32. Leunig M, Goetz AE, Dellian M et al. Interstitial fluid pressure in solid tumors following hyperthermia: possible correlation with therapeutic response. Cancer research 1992; 52: 487–490.
  33. Chua TC, Moran BJ, Sugarbaker PH et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol 2012; 30: 2449–2456.
  34. Gonzales-Moreno S, Sugarbaker PH. Right hemicolectomy does not confer a survival advantage in patients with mucinous carcinoma of the appendix and peritoneal seeding. Br J Surg 2004; 91: 304–311.
  35. Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome. Lancet Oncol 2006; 7: 69–76.
  36. Glehen O, Sugarbaker PH, Elias D et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer. A multi-institutional study of 506 patients. J Clin Oncol 2004; 22: 3284–3292.
  37. Borczuk AC, Taub RN, Hesdorffer M et al. P16 loss and mitotic activity predict poor survival in patients with peritoneal malignant mesothelioma. Clin Cancer Res 2005; 11: 3303–3308.
  38. Deraco M, Cabras A, Baratti D et al. Immunohistochemical evaluation of minichromosome maintance protein 7 (MCM7), topoisomerase II, and Ki-67 in diffuse malignant peritoneal mesothelioma patients using tissue microarray. Ann Surg Oncol 2015; 22: 4344–4351.
  39. Yan TD, Popa E, Brun EA et al. Sex difference in diffuse malignant peritoneal mesothelioma. Br J Surg 2006; 93: 1536–1542.
  40. Deraco M, Baratti D, Hutanu I et al. The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2013; 20: 1093–1100.
  41. Rossi CR, Foletto M, Mocellin S et al. Hyperthermic intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal and sarcomatosis: phase I study. Cancer 2002; 94: 492–499.
  42. Kusamura S, O’Dwyer ST, Baratti D et al. Technical aspects of cytoreductive surgery. J Surg Oncol 2008; 98: 232–236.
  43. Deraco M, Kusamura S, Sugarbaker PH et al. PSOGI International Registry on peritoneal mesothelioma., Eleventh International Symposium on regional Cancer Therapies, Phoenix, 2016.
  44. Chua TC, Yan TD, Saxena A et al. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? A systematic review of morbidity and mortality. Ann Surg 2009; 249: 900–907.
  45. WHO. Globoscan – Section of Cancer Information. International Agency for Research on Cancer, France, 2008. Dostupné na: www.iarc.fr
  46. Koppe MJ, Boerman OC, Oyen WJ et al. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg 2006; 243: 212–222.
  47. Spratt JS, Adcock RA, Muskovin N et al. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res 1980; 40: 256–260.
  48. Verwaal VJ, van Ruth S, de Bree E et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003; 21: 3737–3743.
  49. Elias D, Lefevre JH, Chevalier J et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 2009; 27: 681–685.
  50. Hioki M, Gotohda N, Konishi M et al. Predictive factors improving survival after gastrectomy in gastric cancer patients with peritoneal carcinomatosis. World J Surg 2010; 34: 555–562.
  51. Kodera Y, Yamamura Y, Shimizu Y et al. Peritoneal washing cytology: prognostic value of positive findings in patients with gastric carcinoma undergoing a potentially curative resection. J Surg Oncol 1999; 72: 60–65.
  52. Glehen O, Gilly FN, Arvieux C et al. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol 2010; 17: 2370–2377.
  53. Yonemura Y, Kawamura T, Bandou E et al. Treatment of peritoneal dissemination from gastric cancer by peritonectomy and chemohyperthermic peritoneal perfusion. Br J Surg 2005; 92: 370–375.
  54. Solass W, Kerb R, Mürdter T et al. Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. Ann Surg Oncol 2014; 21: 553–559.
  55. Ferrandina G, Legge F, Salutari V et al. Impact of pattern of recurrence on clinical outcome of ovarian cancer patients: clinical consideration. Eur J Cancer 2006; 42: 2296–2302.
  56. van Driel WJ, Koole SN, Sonke GS. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Eng J Med 2018; 3: 230–240.
  57. Spiliotis J, Halkia E, Lianos E et al. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol 2015; 22: 1570–1575.
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management
Occupational medicine and disease prevention
Diagnostics and acknowledgement of occupational diseases – topics and challenges in the Czech Republic
Risk factors of working environment and occupational diseases reported in the Czech Republic in 2017
Occupational asthma and rhinitis: Do we think about it as soon as possible?
Psychosocial risks in healthcare
Article was published in

Journal of Czech Physicians

Issue 8
2018 Issue 8
Most read in this issue
Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#